Reardon Andrew's Form 4 filing
Ligand Pharmaceuticals Inc (LGND) · filed Jun 2, 2025
- Accession no.
- 0002001011-25-000037
- Filed
- Jun 2, 2025
- Trade date
- Aug 10, 2024-May 15, 2025
- Filing delay
- 296 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $104.0K. It was filed 296 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Reardon AndrewCIK 0001950232 | Officer (CLO & Secretary) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 10, 2024 | Common Stock | FTax withholdingDisposed | −897 | $100.16 | −$89,843.52 | 21,637 | Direct | |
| May 15, 2025 | Common Stock | SSaleDisposed | −1,000 | $104.00 | −$104,000 | 32,903 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.